Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Bladder Cancer, April 2021

Free Subscription


Abstracts

Retrieve all available abstracts of the following 229 articles:
HTML format


 

Single Articles


  1. Corrigendum to: LMTK3 promotes tumorigenesis in bladder cancer via the ERK/MAPK pathway.
    FEBS Open Bio. 2021;11:1277.
    PubMed    


  2. ZHAO Z, Zhang P, Li W, Wang D, et al
    Pegylated Recombinant Human Arginase 1 Induces Autophagy and Apoptosis via the ROS-Activated AKT/mTOR Pathway in Bladder Cancer Cells.
    Oxid Med Cell Longev. 2021;2021:5510663.
    PubMed    
    Abstract available

  3. WANG J, Luo J, Wu X, Gao Z, et al
    Circular RNA_0000629 Suppresses Bladder Cancer Progression Mediating MicroRNA-1290/CDC73.
    Cancer Manag Res. 2021;13:2701-2715.
    PubMed    
    Abstract available

  4. ZHU W, Zhao Z, Feng B, Yu W, et al
    CD8+CD39+ T Cells Mediate Anti-Tumor Cytotoxicity in Bladder Cancer.
    Onco Targets Ther. 2021;14:2149-2161.
    PubMed    
    Abstract available

  5. MORSELLI S, Baria E, Cicchi R, Liaci A, et al
    The feasibility of multimodal fiber optic spectroscopy analysis in bladder cancer detection, grading, and staging.
    Urologia. 2021 Mar 31:3915603211007018. doi: 10.1177/03915603211007018.
    PubMed    
    Abstract available

  6. WANG JG, Zhu ZW, Fan YF, Zhang XP, et al
    [Clinical outcomes for young patients with muscular invasive bladder cancer who received robot-assisted radical cystectomy].
    Zhonghua Yi Xue Za Zhi. 2021;101:861-865.
    PubMed    
    Abstract available

  7. SANCHEZ A, Agarwal N
    Quantifying the Costs of Care Among Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated in the Veterans Health Administration.
    JAMA Netw Open. 2021;4:e213816.
    PubMed    


  8. WILLIAMS SB, Howard LE, Foster ML, Klaassen Z, et al
    Estimated Costs and Long-term Outcomes of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guerin in the Veterans Affairs Health System.
    JAMA Netw Open. 2021;4:e213800.
    PubMed    
    Abstract available

  9. LIU S, Shi J, Liu Y, Wang L, et al
    Analysis of mRNA expression differences in bladder cancer metastasis based on TCGA datasets.
    J Int Med Res. 2021;49:300060521996929.
    PubMed    
    Abstract available

  10. YAKOVLEV PG, Gorbach OI, Khranovska NM, Beliayeva AV, et al
    Changes in expression of TLR-4, TGF-beta, INF-gamma, TNF-alpha in cultured T24/83cells of invasive bladder cancer treated with cisplatin and/or polyphenolic adjuvant melanin.
    Exp Oncol. 2021;43:7-14.
    PubMed    
    Abstract available

  11. ELSAWY AA, Awadalla A, Abdullateef M, Ahmed AE, et al
    Can repeat biopsy be skipped after initial complete resection of T1 bladder cancer? The role of a novel urinary mRNA biomarker.
    Urol Oncol. 2021 Mar 27. pii: S1078-1439(21)00070.
    PubMed    
    Abstract available

  12. KORAC-PRLIC J, Degoricija M, Vilovic K, Vujevic S, et al
    BBN-driven urinary bladder cancer mouse model.
    Methods Cell Biol. 2021;163:77-92.
    PubMed    
    Abstract available

  13. BESSA A, Bosco C, Mehrotra S, Rowland M, et al
    Is there a role for physical activity interventions in the treatment pathway of bladder cancer? A scoping review of the literature.
    BMJ Open Sport Exerc Med. 2021;7:e000951.
    PubMed    
    Abstract available

  14. HENNING GM, Barashi NS, Smith ZL
    Advances in Biomarkers for Detection, Surveillance, and Prognosis of Bladder Cancer.
    Clin Genitourin Cancer. 2021 Mar 4. pii: S1558-7673(21)00003.
    PubMed    
    Abstract available

  15. LIAO Y, Tang H, Wang M, Wang K, et al
    The potential diagnosis role of TP53 mutation in advanced bladder cancer: A meta-analysis.
    J Clin Lab Anal. 2021 Mar 29:e23765. doi: 10.1002/jcla.23765.
    PubMed    
    Abstract available

  16. YANG L, Li A, Liu F, Zhao Q, et al
    Immune Profiling Reveals Molecular Classification and Characteristic in Urothelial Bladder Cancer.
    Front Cell Dev Biol. 2021;9:596484.
    PubMed    
    Abstract available

  17. MOHAMED MB, Ali MH, Shamaa MA, Shaaban SM, et al
    Single course of intravesical Bacillus Calmette-Guerin versus single course with maintenance therapy in the management of nonmuscle invasive bladder cancer: A prospective randomized study.
    Urol Ann. 2020;12:360-365.
    PubMed    
    Abstract available

  18. KUFUKIHARA R, Kikuchi E, Ogihara K, Shigeta K, et al
    ASO Author Reflections: Previous History of Non-urothelial Malignancy May Provide Predictive Information of Worse Clinical Outcome for Initially Diagnosed Non-Muscle Invasive Bladder Cancer.
    Ann Surg Oncol. 2021 Mar 27. pii: 10.1245/s10434-021-09787.
    PubMed    


  19. TEOH JY, Mayor N, Li KM, Lo KL, et al
    En-bloc resection of bladder tumour as primary treatment for patients with non-muscle-invasive bladder cancer: routine implementation in a multi-centre setting.
    World J Urol. 2021 Mar 28. pii: 10.1007/s00345-021-03675.
    PubMed    
    Abstract available

  20. LEBACLE C, Loriot Y, Irani J
    BCG-unresponsive high-grade non-muscle invasive bladder cancer: what does the practicing urologist need to know?
    World J Urol. 2021 Mar 27. pii: 10.1007/s00345-021-03666.
    PubMed    
    Abstract available

  21. GIORDANO G, Kyriazi E, Mavridis C, Persico F, et al
    Oncology and complications.
    Arch Ital Urol Androl. 2021;93:71-76.
    PubMed    
    Abstract available

  22. SARKIS J, Assaf J
    Re: Updates in the management and future landscape of urothelial carcinoma.
    J Oncol Pharm Pract. 2021;27:514-515.
    PubMed    
    Abstract available

  23. SIDAWAY P
    Intravesical therapy goes viral.
    Nat Rev Clin Oncol. 2021;18:64.
    PubMed    


  24. SUN Z, Jing C, Xiao C, Li T, et al
    An autophagy-related long non-coding RNA prognostic signature accurately predicts survival outcomes in bladder urothelial carcinoma patients.
    Aging (Albany NY). 2020;12:15624-15637.
    PubMed    
    Abstract available

  25. BAISAKH MR, Tiwari A, Gandhi JS, Naik S, et al
    Primary round cell sarcomas of the urinary bladder with EWSR1 rearrangement: a multi-institutional study of thirteen cases with a review of the literature.
    Hum Pathol. 2020;104:84-95.
    PubMed    
    Abstract available

  26. KYOYA T, Arnold LL, Pennington KL, Kakiuchi-Kiyota S, et al
    Urinary crystal formation and urothelial effects of pyroxasulfone administered to male rats.
    Toxicol Mech Methods. 2020;30:656-671.
    PubMed    
    Abstract available

  27. MURATA SI, Kuroda M, Kawamura N, Warigaya K, et al
    Microtubule-organizing center-mediated structural atypia in low- and high-grade urothelial carcinoma.
    Virchows Arch. 2021;478:327-334.
    PubMed    
    Abstract available

  28. MAZIARZ M, Park JC, Leyme A, Marivin A, et al
    Revealing the Activity of Trimeric G-proteins in Live Cells with a Versatile Biosensor Design.
    Cell. 2020;182:770-785.
    PubMed    
    Abstract available

  29. LIU L, Zhong X, Cui H, Zhang H, et al
    Identification of an Individualized Prognostic Signature Based on the RWSR Model in Early-Stage Bladder Carcinoma.
    Biomed Res Int. 2020;2020:9186546.
    PubMed    
    Abstract available

  30. ESPEJO-HERRERA N, Condom-Mundo E
    Yolk sac tumor differentiation in urothelial carcinoma of the urinary bladder: a case report and differential diagnosis.
    Diagn Pathol. 2020;15:68.
    PubMed    
    Abstract available

  31. NEAL DJ, Amin MB, Smith SC
    CK20 versus AMACR and p53 immunostains in evaluation of Urothelial Carcinoma in Situ and Reactive Atypia.
    Diagn Pathol. 2020;15:61.
    PubMed    
    Abstract available

  32. MALTAGLIATI M, Varca V, Milandri R, Micali S, et al
    Second-look TURBT: evaluation of anatomopatological and oncologic results in a single center.
    Acta Biomed. 2020;91:322-325.
    PubMed    
    Abstract available

  33. TOWNSEND S, Regier PJ, More SN
    Successful Treatment of Urinary Bladder Hemangiosarcoma by Partial Cystectomy in a Dog.
    J Am Anim Hosp Assoc. 2020;56:231-235.
    PubMed    
    Abstract available

  34. ROBERTS JE
    Techniques to Improve Photodynamic Therapy.
    Photochem Photobiol. 2020;96:524-528.
    PubMed    
    Abstract available

  35. FENG Y, Jiang Y, Wen T, Meng F, et al
    Identifying Potential Prognostic Markers for Muscle-Invasive Bladder Urothelial Carcinoma by Weighted Gene Co-Expression Network Analysis.
    Pathol Oncol Res. 2020;26:1063-1072.
    PubMed    
    Abstract available

  36. PETRELLI F, Giannatempo P, Maccagnano C, Contieri R, et al
    Active surveillance for non-muscle invasive bladder cancer: A systematic review and pooled-analysis.
    Cancer Treat Res Commun. 2021;27:100369.
    PubMed    
    Abstract available

  37. RUF P, Bauer HW, Schoberth A, Kellermann C, et al
    First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non-muscle invasive bladder cancer indicates high tolerability and local immunological activity.
    Cancer Immunol Immunother. 2021 Apr 10. pii: 10.1007/s00262-021-02930.
    PubMed    
    Abstract available

  38. SANG J, Li W, Diao HJ, Fan RZ, et al
    Jolkinolide B targets thioredoxin and glutathione systems to induce ROS-mediated paraptosis and apoptosis in bladder cancer cells.
    Cancer Lett. 2021 Apr 6. pii: S0304-3835(21)00153.
    PubMed    
    Abstract available

  39. ABUSHAMMA F, Khayyat Z, Soroghle A, H Zyoud S, et al
    The Impact of Non-Compliance to a Standardized Risk-Adjusted Protocol on Recurrence, Progression, and Mortality in Non-Muscle Invasive Bladder Cancer.
    Cancer Manag Res. 2021;13:2937-2945.
    PubMed    
    Abstract available

  40. CAO G, Zhang C, Tian X, Jing G, et al
    circCEP128 Knockdown Suppresses Bladder Cancer Progression via Regulating microRNA-515-5p/SDC1 Axis.
    Cancer Manag Res. 2021;13:2885-2896.
    PubMed    
    Abstract available

  41. XU W, Anwaier A, Ma C, Liu W, et al
    Multi-omics reveals novel prognostic implication of SRC protein expression in bladder cancer and its correlation with immunotherapy response.
    Ann Med. 2021;53:596-610.
    PubMed    
    Abstract available

  42. YANG WX, Shao YX, Hu X, Xiong SC, et al
    [A Randomized Controlled Study of Intravesical Instillation Therapy of Bacillus Calmette-Guerin vs. Epirubicinin Treating Non-muscular Invasive Bladder Cancer].
    Sichuan Da Xue Xue Bao Yi Xue Ban. 2021;52:326-333.
    PubMed    
    Abstract available

  43. WANG Y, Yan K, Wang J, Lin J, et al
    M2 Macrophage Co-Expression Factors Correlate With Immune Phenotype and Predict Prognosis of Bladder Cancer.
    Front Oncol. 2021;11:609334.
    PubMed    
    Abstract available

  44. VALDES A, Bitzios A, Kassa E, Shevchenko G, et al
    Proteomic comparison between different tissue preservation methods for identification of promising biomarkers of urothelial bladder cancer.
    Sci Rep. 2021;11:7595.
    PubMed    
    Abstract available

  45. HIRASAWA Y, Pagano I, Chen R, Sun Y, et al
    Diagnostic performance of Oncuria, a urinalysis test for bladder cancer.
    J Transl Med. 2021;19:141.
    PubMed    
    Abstract available


  46. Retraction: High LINC01605 expression predicts poor prognosis and promotes tumor progression via upregulation of MMP9 in bladder cancer.
    Biosci Rep. 2021;41.
    PubMed    
    Abstract available


  47. Expression of Concern: CircRNA circPDSS1 promotes bladder cancer by downregulating miR-16.
    Biosci Rep. 2021;41.
    PubMed    


  48. KOMYAKOV BK, Al-Attar TH, Dorofeev SY, Semeyko DP, et al
    [A total replacement of the both ureters and urinary bladder by ileal conduit in a woman with contracted bladder and Ormonds disease].
    Urologiia. 2021;:107-111.
    PubMed    
    Abstract available

  49. SARRIO SANZ P, Sanchez Caballero L, Perez Tomas C, Nakdali Kassab B, et al
    [Metabolic alterations and stones in patients with orthotopic ileal diversions. Case description.]
    Arch Esp Urol. 2021;74:351-354.
    PubMed    
    Abstract available

  50. TRAVASSOS TC, De Oliveira JMI, Selegatto IB, Reis LO, et al
    COVID-19 impact on bladder cancer-orientations for diagnosing, decision making, and treatment.
    Am J Clin Exp Urol. 2021;9:132-139.
    PubMed    
    Abstract available

  51. ZHUANG C, Zhuang C, Zhou Q, Huang X, et al
    Engineered CRISPR/Cas13d Sensing hTERT Selectively Inhibits the Progression of Bladder Cancer In Vitro.
    Front Mol Biosci. 2021;8:646412.
    PubMed    
    Abstract available

  52. ZHANG Y, Zhu Y, Xiao M, Cheng Y, et al
    The Long Non-coding RNA TMPO-AS1 Promotes Bladder Cancer Growth and Progression via OTUB1-Induced E2F1 Deubiquitination.
    Front Oncol. 2021;11:643163.
    PubMed    
    Abstract available

  53. KANG Y, Zhu X, Wang X, Liao S, et al
    Identification and Validation of the Prognostic Stemness Biomarkers in Bladder Cancer Bone Metastasis.
    Front Oncol. 2021;11:641184.
    PubMed    
    Abstract available

  54. AGRAWAL P, Jain A, Gautam A, Nigam AK, et al
    A retrospective study to assess the risk of bladder cancer in type-2 diabetic patients treated with pioglitazone.
    Perspect Clin Res. 2021;12:9-13.
    PubMed    
    Abstract available

  55. WANG X, Pan L, Lu Q, Huang H, et al
    A combination of ssGSEA and mass cytometry identifies immune microenvironment in muscle-invasive bladder cancer.
    J Clin Lab Anal. 2021 Apr 4:e23754. doi: 10.1002/jcla.23754.
    PubMed    
    Abstract available

  56. PINTO J, Carapito A, Amaro F, Lima AR, et al
    Discovery of Volatile Biomarkers for Bladder Cancer Detection and Staging through Urine Metabolomics.
    Metabolites. 2021;11.
    PubMed    
    Abstract available

  57. HERRANZ R, Oto J, Plana E, Fernandez-Pardo A, et al
    Circulating Cell-Free DNA in Liquid Biopsies as Potential Biomarker for Bladder Cancer: A Systematic Review.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  58. IBRAHIM OM, Basse PH, Jiang W, Guru K, et al
    NFkappaB-Activated COX2/PGE2/EP4 Axis Controls the Magnitude and Selectivity of BCG-Induced Inflammation in Human Bladder Cancer Tissues.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  59. WONG VK, Ganeshan D, Jensen CT, Devine CE, et al
    Imaging and Management of Bladder Cancer.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  60. FERRO M, La Civita E, Liotti A, Cennamo M, et al
    Liquid Biopsy Biomarkers in Urine: A Route towards Molecular Diagnosis and Personalized Medicine of Bladder Cancer.
    J Pers Med. 2021;11.
    PubMed    
    Abstract available

  61. KIM SY, Hwangbo H, Kim MY, Ji SY, et al
    Betulinic Acid Restricts Human Bladder Cancer Cell Proliferation In Vitro by Inducing Caspase-Dependent Cell Death and Cell Cycle Arrest, and Decreasing Metastatic Potential.
    Molecules. 2021;26.
    PubMed    
    Abstract available

  62. GLUKHOV A, Potoldykova N, Taratkin M, Gordeev S, et al
    Detection of Urothelial Bladder Cancer Based on Urine and Tissue Telomerase Activity Measured by Novel RT-TRAP-2PCR Method.
    J Clin Med. 2021;10.
    PubMed    
    Abstract available

  63. STEMPOR PA, Avni D, Leibowitz R, Sidi Y, et al
    Comprehensive Analysis of Correlations in the Expression of miRNA Genes and Immune Checkpoint Genes in Bladder Cancer Cells.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available

  64. TRATNJEK L, Jeruc J, Romih R, Zupancic D, et al
    Vitamin A and Retinoids in Bladder Cancer Chemoprevention and Treatment: A Narrative Review of Current Evidence, Challenges and Future Prospects.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available

  65. ABOUELKHEIR RT, Abdelhamid A, Abou El-Ghar M, El-Diasty T, et al
    Imaging of Bladder Cancer: Standard Applications and Future Trends.
    Medicina (Kaunas). 2021;57.
    PubMed    
    Abstract available

  66. GEORGANTZOGLOU N, Pergaris A, Masaoutis C, Theocharis S, et al
    Extracellular Vesicles as Biomarkers Carriers in Bladder Cancer: Diagnosis, Surveillance, and Treatment.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available

  67. JOU YC, Wang SC, Dia YC, Wang ST, et al
    Anti-Cancer Effects and Tumor Marker Role of Glutathione S-Transferase Mu 5 in Human Bladder Cancer.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available

  68. MORALES L, Paramio JM
    Cell Therapies in Bladder Cancer Management.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available

  69. DE JONG FC, Rutten VC, Zuiverloon TCM, Theodorescu D, et al
    Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available

  70. ZHANG H, Zhang J, Guo B, Chen H, et al
    The Antitumor Effects of Plasma-Activated Saline on Muscle-Invasive Bladder Cancer Cells In Vitro and In Vivo Demonstrate Its Feasibility as a Potential Therapeutic Approach.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  71. YANG Y, Zou X, Wang Y, Ma X, et al
    Application of deep learning as a noninvasive tool to differentiate muscle-invasive bladder cancer and non-muscle-invasive bladder cancer with CT.
    Eur J Radiol. 2021;139:109666.
    PubMed    
    Abstract available

  72. LUO WJ, Tian X, Xu WH, Qu YY, et al
    Construction of an immune-related LncRNA signature with prognostic significance for bladder cancer.
    J Cell Mol Med. 2021 Apr 1. doi: 10.1111/jcmm.16494.
    PubMed    
    Abstract available

  73. YANG Y, Liu C, Yan X, Li J, et al
    En Bloc Tumor Resection, Optical Molecular Imaging, and the Potential Synergy of the Combination of the Two Techniques in Bladder Cancer.
    Front Oncol. 2021;11:638083.
    PubMed    
    Abstract available

  74. LARA MOSCOLONI LF, Santarelli M, Spagnuolo J
    Tuberculous epididymo-orchitis secondary to Bacillus Calmette-Guerin (BCG) in non-muscular invasive bladder cancer.
    Urol Case Rep. 2021;37:101629.
    PubMed    
    Abstract available

  75. WANG Y, Li X, Chen W, Wu W, et al
    The common region of lncRNAs UCA1 and UCA1alpha contributes to the bladder cancer tumorigenesis.
    Eur J Cancer Prev. 2021 Mar 31. pii: 00008469-900000000-99056.
    PubMed    
    Abstract available

  76. CAUSA ANDRIEU PI, Tzeng M
    Inguinal hernia plugs mimicking abdominal wall invasion of bladder cancer - a potential imaging pitfall.
    Radiologia. 2021 Mar 29. pii: S0033-8338(21)00072.
    PubMed    


  77. GALLEGOS H, Rojas PA, Sepulveda F, Zuniga A, et al
    Protective role of intravesical BCG in COVID-19 severity.
    BMC Urol. 2021;21:50.
    PubMed    
    Abstract available

  78. MUKHERJEE S, Abbaraju J, Russell G, Madaan S, et al
    Bladder-to-bladder metastasis: gallbladder cancer metastasising to the urinary bladder.
    Ann R Coll Surg Engl. 2021;103:e116-e119.
    PubMed    
    Abstract available

  79. BRISOTTO G, Guerrieri R, Colizzi F, Steffan A, et al
    Long Noncoding RNAs as Innovative Urinary Diagnostic Biomarkers.
    Methods Mol Biol. 2021;2292:73-94.
    PubMed    
    Abstract available

  80. BRAVACCINI S
    Fluorescence In Situ Hybridization in Urine Samples (UroVysion Kit).
    Methods Mol Biol. 2021;2292:35-48.
    PubMed    
    Abstract available

  81. O'LEARY K
    MYC inhibition, courtesy of E. coli.
    Nat Rev Cancer. 2021;21:214-215.
    PubMed    


  82. HUANG WB, Cheng L
    [Variants of urothelial carcinoma: new molecular insight and differential diagnosis].
    Zhonghua Bing Li Xue Za Zhi. 2021;50:155-158.
    PubMed    


  83. TORRES-JIMENEZ J, Albarran-Fernandez V, Pozas J, Roman-Gil MS, et al
    Novel Tyrosine Kinase Targets in Urothelial Carcinoma.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available

  84. KIM B, Jang I, Kim K, Jung M, et al
    Comprehensive Gene Expression Analyses of Immunohistochemically Defined Subgroups of Muscle-Invasive Urinary Bladder Urothelial Carcinoma.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available

  85. BONTOUX C, Rialland T, Cussenot O, Comperat E, et al
    A four-antibody immunohistochemical panel can distinguish clinico-pathological clusters of urothelial carcinoma and reveals high concordance between primary tumor and lymph node metastases.
    Virchows Arch. 2021;478:637-645.
    PubMed    
    Abstract available

  86. REXER H, Bedke J, Merseburger A

    Aktuelle Urol. 2020;51:418-420.
    PubMed    


  87. THEN CK, Paillas S, Wang X, Hampson A, et al
    Association of Bacteroides acidifaciens relative abundance with high-fibre diet-associated radiosensitisation.
    BMC Biol. 2020;18:102.
    PubMed    
    Abstract available

  88. MALLY D, Paffenholz P
    [Complication management for TUR of the bladder].
    Aktuelle Urol. 2020;51:450-455.
    PubMed    
    Abstract available

  89. ALI MS, Metwally AA, Fahmy RH, Osman R, et al
    Chitosan-coated nanodiamonds: Mucoadhesive platform for intravesical delivery of doxorubicin.
    Carbohydr Polym. 2020;245:116528.
    PubMed    
    Abstract available

  90. RUDOLPH J, Martini T, Wezel F
    [The impact of radical cystectomy on health-related quality of life and potential for optimisation].
    Aktuelle Urol. 2020;51:363-370.
    PubMed    
    Abstract available

  91. CIMADAMORE A, Aurilio G, Nole F, Massari F, et al
    Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer.
    Cells. 2020;9.
    PubMed    
    Abstract available

  92. HENNIG MJP, Kramer MW
    [Potential for improvement by new resection and imaging techniques in TUR-B].
    Aktuelle Urol. 2020;51:348-352.
    PubMed    
    Abstract available

  93. XIA CS, Fan CH, Su M, Wang QS, et al
    Use of the Nuclear Matrix Protein 22 BladderChek Test for the Detection of Primary and Recurrent Urothelial Carcinoma.
    Dis Markers. 2020;2020:3424039.
    PubMed    
    Abstract available

  94. QIN Q, Patel V, Galsky MD
    Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors.
    Expert Rev Anticancer Ther. 2020;20:503-512.
    PubMed    
    Abstract available

  95. SCHUETTFORT V, Shariat SF, Rink M
    [Surgery only? Multimodal treatment for urothelial carcinoma of the bladder].
    Aktuelle Urol. 2020;51:353-362.
    PubMed    
    Abstract available

  96. FREIH-FRAIH A, Munoz-Hernandez P, Gordillo CH, Jimenez-Heffernan JA, et al
    Iatrogenic granulomatous changes in voided urine cytology.
    Diagn Cytopathol. 2020;48:687-689.
    PubMed    


  97. GRUNEWALD CM, Hiester A, Niegisch G
    [Systemic therapy for metastatic urothelial carcinoma - Current status and what comes after checkpoint inhibitors?]
    Aktuelle Urol. 2020;51:371-376.
    PubMed    
    Abstract available

  98. ELDIN ME, Makboul R, Behnsawy HM, Abdelkawi IF, et al
    Comparative Application of Different Substaging Techniques for Non-Muscle Invasive Urothelial Carcinoma.
    Pathol Oncol Res. 2020;26:1823-1831.
    PubMed    
    Abstract available

  99. LENFANT L, Campi R, Parra J, Graffeille V, et al
    Robotic versus open radical cystectomy throughout the learning phase: insights from a real-life multicenter study.
    World J Urol. 2020;38:1951-1958.
    PubMed    
    Abstract available

  100. GONTERO P, Pisano F, Palou J, Joniau S, et al
    Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases.
    World J Urol. 2020;38:1959-1968.
    PubMed    
    Abstract available

  101. HOU G, Zheng Y, Zhang L, Lai D, et al
    Development and validation of a prognostic nomogram for patients with intravesical recurrence after radical nephroureterectomy for non-metastatic upper tract urothelial carcinoma.
    World J Urol. 2020;38:1969-1975.
    PubMed    
    Abstract available

  102. HSIAO BY, Su SY, Jhuang JR, Chiang CJ, et al
    Ensemble forecasting of a continuously decreasing trend in bladder cancer incidence in Taiwan.
    Sci Rep. 2021;11:8373.
    PubMed    
    Abstract available

  103. LINDSKROG SV, Prip F, Lamy P, Taber A, et al
    An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer.
    Nat Commun. 2021;12:2301.
    PubMed    
    Abstract available

  104. APPLEYARD SE, Nikapota AD
    Patient-Reported Outcomes and Health-Related Quality of Life Following Radiotherapy for Bladder Cancer.
    Clin Oncol (R Coll Radiol). 2021 Apr 13. pii: S0936-6555(21)00107.
    PubMed    
    Abstract available

  105. KORKES F, Fernandes E, Gushiken FA, Glina FPA, et al
    Bricker ileal conduit vs. Cutaneous ureterostomy after radical cystectomy for bladder cancer: a systematic review.
    Int Braz J Urol. 2021;47.
    PubMed    
    Abstract available

  106. CAO Y, Hu Q, Zhang R, Li L, et al
    Knockdown of Long Non-coding RNA SNGH3 by CRISPR-dCas9 Inhibits the Progression of Bladder Cancer.
    Front Mol Biosci. 2021;8:657145.
    PubMed    
    Abstract available

  107. BOLETO G, Avouac J, Allanore Y
    Rapidly Progressive Systemic Sclerosis-associated Interstitial Lung Disease After Intravesical Bacillus Calmette-Guerin Therapy for Early-stage Bladder Cancer.
    J Rheumatol. 2021 Apr 15. pii: jrheum.201625. doi: 10.3899/jrheum.201625.
    PubMed    
    Abstract available

  108. WOLDU SL, Souter L, Boorjian SA, Barocas DA, et al
    Urinary-based tumor markers enhance microhematuria risk stratification according to baseline bladder cancer prevalence.
    Urol Oncol. 2021 Apr 12. pii: S1078-1439(21)00132.
    PubMed    
    Abstract available

  109. IYYANKI T, Zhang B, Wang Q, Hou Y, et al
    Subtype-associated epigenomic landscape and 3D genome structure in bladder cancer.
    Genome Biol. 2021;22:105.
    PubMed    
    Abstract available

  110. YANG J, Xia A, Zhang H, Liu Q, et al
    Up-Regulating ERIC by CRISPR-dCas9-VPR Inhibits Cell Proliferation and Invasion and Promotes Apoptosis in Human Bladder Cancer.
    Front Mol Biosci. 2021;8:654718.
    PubMed    
    Abstract available

  111. YANG J, Li C, Tang Y, Guo F, et al
    Diagnostic roles of proliferative markers in pathological Grade of T1 Urothelial Bladder Cancer.
    J Cancer. 2021;12:2498-2506.
    PubMed    
    Abstract available

  112. XIE F, Huang C, Liu F, Zhang H, et al
    CircPTPRA blocks the recognition of RNA N(6)-methyladenosine through interacting with IGF2BP1 to suppress bladder cancer progression.
    Mol Cancer. 2021;20:68.
    PubMed    
    Abstract available

  113. CHAI X, Zhang JW, Li SH, Cheng QS, et al
    Xanthoceraside induces cell apoptosis through downregulation of the PI3K/Akt/Bcl-2/Bax signaling pathway in cell lines of human bladder cancer.
    Indian J Pathol Microbiol. 2021;64:294-301.
    PubMed    
    Abstract available

  114. AURILIO G, Cimadamore A, Lopez-Beltran A, Scarpelli M, et al
    Narrative review: update on immunotherapy and pathological features in patients with bladder cancer.
    Transl Androl Urol. 2021;10:1521-1529.
    PubMed    
    Abstract available

  115. HUANG M, Long Y, Jin Y, Ya W, et al
    Comprehensive analysis of the lncRNA-miRNA-mRNA regulatory network for bladder cancer.
    Transl Androl Urol. 2021;10:1286-1301.
    PubMed    
    Abstract available

  116. ZHAO K, Zhang Q, Zeng T, Zhang J, et al
    Identification and validation of a prognostic immune-related lncRNA signature in bladder cancer.
    Transl Androl Urol. 2021;10:1229-1240.
    PubMed    
    Abstract available

  117. TOMIOKA M, Yoneyama T, Tobisawa Y, Kawase K, et al
    Ghrelin after chemotherapy as a prognostic predictor of progression-free survival in patients with muscle-invasive bladder cancer.
    Transl Androl Urol. 2021;10:1192-1201.
    PubMed    
    Abstract available

  118. IWAMURA H, Hatakeyama S, Momota M, Kojima Y, et al
    Relationship of frailty with treatment modality selection in patients with muscle-invasive bladder cancer (FRART-BC study).
    Transl Androl Urol. 2021;10:1143-1151.
    PubMed    
    Abstract available

  119. REYES RM, Deng Y, Zhang D, Ji N, et al
    CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from alphaPD-L1 and include tissue-selective gammadelta T cell activation.
    J Immunother Cancer. 2021;9.
    PubMed    
    Abstract available

  120. HAMMOUDA K, Khalifa F, Soliman A, Ghazal M, et al
    A multiparametric MRI-based CAD system for accurate diagnosis of bladder cancer staging.
    Comput Med Imaging Graph. 2021;90:101911.
    PubMed    
    Abstract available

  121. KORKES F
    Editorial Comment: Factors associated with utilization of neoadjuvant chemotherapy in charlson comorbidity zero non-metastatic muscle-invasive bladder cancer patients.
    Int Braz J Urol. 2021;47:819-820.
    PubMed    


  122. AU D, Lee EK, Popoola TO, Parker WP, et al
    Factors associated with utilization of neoadjuvant chemotherapy in charlson comorbidity zero non-metastatic muscle-invasive bladder cancer patients.
    Int Braz J Urol. 2021;47:803-818.
    PubMed    
    Abstract available

  123. DU Y, Zhang X, Zhang H, Chen Y, et al
    Propofol modulates the proliferation, invasion and migration of bladder cancer cells through the miR1455p/TOP2A axis.
    Mol Med Rep. 2021;23.
    PubMed    
    Abstract available

  124. ZHENG P, Wu K, Gao Z, Li H, et al
    KIF4A promotes the development of bladder cancer by transcriptionally activating the expression of CDCA3.
    Int J Mol Med. 2021;47.
    PubMed    
    Abstract available

  125. RODRIGUES PESSOA R, Mueller AC, Boxley P, Flaig TW, et al
    Systematic review and meta-analysis of radiation therapy for high-risk non-muscle invasive bladder cancer.
    Urol Oncol. 2021 Apr 10. pii: S1078-1439(21)00118.
    PubMed    
    Abstract available

  126. WANG G, Dai Y, Li K, Cheng M, et al
    Corrigendum: Deficiency of Mettl3 in Bladder Cancer Stem Cells Inhibits Bladder Cancer Progression and Angiogenesis.
    Front Cell Dev Biol. 2021;9:675417.
    PubMed    
    Abstract available

  127. ADAMKIEWICZ M, Bryniarski P, Kowalik M, Burzynski B, et al
    Lymphocyte-to-Monocyte Ratio Is the Independent Prognostic Marker of Progression in Patients Undergoing BCG-Immunotherapy for Bladder Cancer.
    Front Oncol. 2021;11:655000.
    PubMed    
    Abstract available

  128. WU J, Wen JM, Wang YC, Luo WJ, et al
    Prognostic Value of an Immunohistochemical Signature in Patients With Bladder Cancer Undergoing Radical Cystectomy.
    Front Oncol. 2021;11:641385.
    PubMed    
    Abstract available

  129. YANG J, Lin J, An J, Zhao Y, et al
    TRIB3 Promotes the Malignant Progression of Bladder Cancer: An Integrated Analysis of Bioinformatics and in vitro Experiments.
    Front Genet. 2021;12:649208.
    PubMed    
    Abstract available

  130. VARUGHESE M
    Overcoming the Chasm Between Evidence and Routine Practice for Bladder Cancer; Just a Quixotic Notion?
    Clin Oncol (R Coll Radiol). 2021 Apr 8. pii: S0936-6555(21)00099.
    PubMed    
    Abstract available

  131. DOGAN C, Yazici CM, Akgul M, Turker P, et al
    The Evaluation of the Relation between Bladder Cancer and Oxidative Stress Using NRF-2/KEAP-1 Pathway, Zinc and Copper Levels.
    Urol J. 2021 Apr 11:6439. doi: 10.22037/uj.v18i.6439.
    PubMed    
    Abstract available

  132. RAZZAGHI MR, Mazloomfard MM, Yavar M, Malekian S, et al
    Holmium LASER in Comparison with Transurethral Resection of the Bladder Tumor for Non-muscle Invasive Bladder Cancer: Randomized Clinical Trial with 18-month Follow-up.
    Urol J. 2021 Apr 11. pii: 6319. doi: 10.22037/uj.v18i.6319.
    PubMed    
    Abstract available

  133. ROYCE TJ, Liu Y, Milowsky MI, Efstathiou JA, et al
    Trimodality Therapy With or Without Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2021 Mar 16. pii: S1558-7673(21)00070.
    PubMed    
    Abstract available

  134. KOBAYASHI H, Tsuchiyama K, Taga M, Tokunaga T, et al
    Impact of self-decision to stop cancer treatment on advanced genitourinary cancer patients.
    Medicine (Baltimore). 2021;100:e25397.
    PubMed    
    Abstract available

  135. CHENG K, Yang WR, Jiang SJ, Shen Q, et al
    [Diagnosis of large cell neuroendocrine carcinoma by urine cytology: report of a case].
    Zhonghua Bing Li Xue Za Zhi. 2021;50:408-410.
    PubMed    


  136. XIA Y, Liu Y, Yang C, Simeone DM, et al
    Dominant role of CDKN2B/p15INK4B of 9p21.3 tumor suppressor hub in inhibition of cell-cycle and glycolysis.
    Nat Commun. 2021;12:2047.
    PubMed    
    Abstract available

  137. JENDOUZI O, Boukhlifi Y, Houadfi OE, Essaoudi MA, et al
    Bladder lipoma: Moroccan case report.
    Pan Afr Med J. 2020;37:380.
    PubMed    
    Abstract available

  138. MA X, Huang R, Wu X, Zhang P, et al
    Dualmarker: a flexible toolset for exploratory analysis of combinatorial dual biomarkers for clinical efficacy.
    BMC Bioinformatics. 2021;22:127.
    PubMed    
    Abstract available

  139. IKARI R, Mukaisho KI, Kageyama S, Nagasawa M, et al
    Differences in the Central Energy Metabolism of Cancer Cells between Conventional 2D and Novel 3D Culture Systems.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available

  140. GARCIA-ROJO E, Manfredi C, Santos-Perez-de-la-Blanca R, Tejido-Sanchez A, et al
    Impact of COVID-19 outbreak on urology surgical waiting lists and waiting lists prioritization strategies in the Post-COVID-19 era.
    Actas Urol Esp. 2021;45:207-214.
    PubMed    
    Abstract available

  141. STRUCK JP, Kramer MW, Katzendorn O, Hupe MC, et al
    Bicentric Retrospective Analysis of en Bloc Resection and Muscularis Mucosae Detection Rate in Non-Muscle Invasive Bladder Tumors: A Real-World Scenario.
    Adv Ther. 2021;38:258-267.
    PubMed    
    Abstract available

  142. MOLLICA V, Maggio I, Lopez-Beltran A, Montironi R, et al
    Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors.
    Expert Rev Anticancer Ther. 2020;20:755-763.
    PubMed    
    Abstract available

  143. CZUB P, Budnik M, Majstrak F, Kochanowski J, et al
    Echocardiographic photorealistic imaging of leiomyomatosis intravascularis.
    Int J Cardiovasc Imaging. 2021;37:109-111.
    PubMed    
    Abstract available

  144. NIAZI MKK, Yazgan E, Tavolara TE, Li W, et al
    Semantic segmentation to identify bladder layers from H&E Images.
    Diagn Pathol. 2020;15:87.
    PubMed    
    Abstract available

  145. REN C, Wang X, Yang C, Li S, et al
    Investigation of Atyp.C using UF-5000 flow cytometer in patients with a suspected diagnosis of urothelial carcinoma: a single-center study.
    Diagn Pathol. 2020;15:77.
    PubMed    
    Abstract available

  146. OSHINA T, Kawai T, Sato Y, Miyakawa J, et al
    Inverted papilloma of the urinary bladder shows fluorescence on photodynamic diagnosis using 5-aminolevulinic acid.
    Photodiagnosis Photodyn Ther. 2020;30:101766.
    PubMed    
    Abstract available

  147. KIRK PS, Liu X, Borza T, Li BY, et al
    Dynamic readmission prediction using routine postoperative laboratory results after radical cystectomy.
    Urol Oncol. 2020;38:255-261.
    PubMed    
    Abstract available

  148. NARAYAN VM, Seif MA, Lim AH, Li R, et al
    Radical cystectomy in women: Impact of the robot-assisted versus open approach on surgical outcomes.
    Urol Oncol. 2020;38:247-254.
    PubMed    
    Abstract available

  149. REESE SW, Ji E, Paciotti M, Leow JJ, et al
    Risk factors and reasons for reoperation after radical cystectomy.
    Urol Oncol. 2020;38:269-277.
    PubMed    
    Abstract available

  150. LI M, Toniolo J, Nandurkar R, Papa N, et al
    Continuous bladder irrigation after transurethral resection of non-muscle invasive bladder cancer for prevention of tumour recurrence: a systematic review.
    ANZ J Surg. 2021 Apr 23. doi: 10.1111/ans.16740.
    PubMed    
    Abstract available

  151. VANARSA K, Enan S, Patel P, Strachan B, et al
    Urine protein biomarkers of bladder cancer arising from 16-plex antibody-based screens.
    Oncotarget. 2021;12:783-790.
    PubMed    
    Abstract available

  152. QU G, Liu Z, Yang G, Xu Y, et al
    Development of a prognostic index and screening of prognosis related genes based on an immunogenomic landscape analysis of bladder cancer.
    Aging (Albany NY). 2021;13.
    PubMed    
    Abstract available

  153. LEIVO MZ, Tacha DE, Hansel DE
    Expression of Uroplakin II and GATA-3 in Bladder Cancer Mimickers: Caveats in the Use of a Limited Panel to Determine Cell of Origin in Bladder Lesions.
    Hum Pathol. 2021 Apr 19. pii: S0046-8177(21)00057.
    PubMed    
    Abstract available

  154. MONAGHAN TF, Robins DJ, Suss NR, Miller CD, et al
    Determinants of neoadjuvant chemotherapy for urothelial muscle-invasive bladder cancer: Does location matter?
    Int J Clin Pract. 2021 Apr 22:e14262. doi: 10.1111/ijcp.14262.
    PubMed    
    Abstract available

  155. CHEN J, Hao L, Zhang S, Zhang Y, et al
    Preoperative Fibrinogen-Albumin Ratio, Potential Prognostic Factors for Bladder Cancer Patients Undergoing Radical Cystectomy: A Two-Center Study.
    Cancer Manag Res. 2021;13:3181-3192.
    PubMed    
    Abstract available

  156. PIATTI P, Chew YC, Suwoto M, Yamada T, et al
    Clinical evaluation of Bladder CARE, a new epigenetic test for bladder cancer detection in urine samples.
    Clin Epigenetics. 2021;13:84.
    PubMed    
    Abstract available

  157. LILLY E, El Gharib K
    Immunotherapy and non-muscle-invasive bladder cancer: an idea from the 19(th) century.
    Expert Rev Anticancer Ther. 2021 Apr 21. doi: 10.1080/14737140.2021.1921578.
    PubMed    


  158. RAZIK A, Das CJ, Das CJ, Sharma R, et al
    Utility of first order MRI-Texture analysis parameters in the prediction of histologic grade and muscle invasion in urinary bladder cancer: A preliminary study.
    Br J Radiol. 2021 Apr 21:20201114. doi: 10.1259/bjr.20201114.
    PubMed    
    Abstract available

  159. ZHANG Y, Luo G, You S, Zhang L, et al
    Exosomal LINC00355 derived from cancer-associated fibroblasts promotes bladder cancer cell proliferation and invasion by regulating miR-15a-5p/HMGA2 axis.
    Acta Biochim Biophys Sin (Shanghai). 2021 Apr 21. pii: 6244475.
    PubMed    
    Abstract available

  160. ZALEWSKA-ADAMIEC M, Klonowska P, Malyszko J, Kuzma L, et al
    Primary Takotsubo Syndrome as a Complication of Bladder Cancer Treatment in a 62-Year-Old Woman.
    Am J Case Rep. 2021;22:e930090.
    PubMed    
    Abstract available

  161. ZHANG H, Xiao X, Wei W, Huang C, et al
    CircLIFR synergizes with MSH2 to attenuate chemoresistance via MutSalpha/ATM-p73 axis in bladder cancer.
    Mol Cancer. 2021;20:70.
    PubMed    
    Abstract available

  162. YAHYAZADEH R, Bashash D, Ghaffari P, Kord S, et al
    Evaluation of hTERT, KRT7, and survivin in urine for noninvasive detection of bladder cancer using real-time PCR.
    BMC Urol. 2021;21:64.
    PubMed    
    Abstract available

  163. THAKUR ML, Tripathi SK, Gomella LG, Salmanoglu E, et al
    Imaging urothelial bladder cancer: A VPAC PET targeted approach.
    Can J Urol. 2021;28:10596-10602.
    PubMed    
    Abstract available

  164. ZHANG C, Hu J, Li H, Ma H, et al
    Emerging Biomarkers for Predicting Bladder Cancer Lymph Node Metastasis.
    Front Oncol. 2021;11:648968.
    PubMed    
    Abstract available

  165. WAN J, Guo C, Fang H, Xu Z, et al
    Autophagy-Related Long Non-coding RNA Is a Prognostic Indicator for Bladder Cancer.
    Front Oncol. 2021;11:647236.
    PubMed    
    Abstract available

  166. PAK S, Kim SY, Kim SH, Joung JY, et al
    Association Between Antibiotic Treatment and the Efficacy of Intravesical BCG Therapy in Patients With High-Risk Non-Muscle Invasive Bladder Cancer.
    Front Oncol. 2021;11:570077.
    PubMed    
    Abstract available

  167. VERMA A, Mittal RD
    Association of miRNA 30c, miRNA 181a and miRNA 570 SNPs with Bladder Cancer Risk in North Indian Population: A Pilot Study.
    Indian J Clin Biochem. 2021;36:194-199.
    PubMed    
    Abstract available

  168. LONATI C, Baumeister P, Ornaghi PI, Di Trapani E, et al
    Accuracy of Transurethral Resection of the Bladder in Detecting Variant Histology of Bladder Cancer Compared with Radical Cystectomy.
    Eur Urol Focus. 2021 Apr 15. pii: S2405-4569(21)00111.
    PubMed    
    Abstract available

  169. SOLANKI AA, Venkatesulu BP, Efstathiou JA
    Will the Use of Biomarkers Improve Bladder Cancer Radiotherapy Delivery?
    Clin Oncol (R Coll Radiol). 2021 Apr 16. pii: S0936-6555(21)00108.
    PubMed    
    Abstract available

  170. PAK JS, Haas CR, Anderson CB, DeCastro GJ, et al
    Survival and oncologic outcomes of complete transurethral resection of bladder tumor prior to neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Urol Oncol. 2021 Apr 14. pii: S1078-1439(21)00135.
    PubMed    
    Abstract available

  171. KATO S, Fushimi K, Yabuki Y, Maru Y, et al
    Precision modeling of gall bladder cancer patients in mice based on orthotopic implantation of organoid-derived tumor buds.
    Oncogenesis. 2021;10:33.
    PubMed    
    Abstract available

  172. RESNIK N, Tratnjek L, Kreft ME, Kisovec M, et al
    Cytotoxic Activity of LLO Y406A Is Targeted to the Plasma Membrane of Cancer Urothelial Cells.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available

  173. BERNING L, Schlutermann D, Friedrich A, Berleth N, et al
    Prodigiosin Sensitizes Sensitive and Resistant Urothelial Carcinoma Cells to Cisplatin Treatment.
    Molecules. 2021;26.
    PubMed    
    Abstract available

  174. RICCETTO CLZ
    Editorial Comment: Combination therapy in overacti-ve bladder-untapped research opportunities: A systematic review of the literature.
    Int Braz J Urol. 2021;47:661-662.
    PubMed    


  175. CAPIBARIBE DM, Dal Col LSB, Jalalizadeh M, Reis LO, et al
    How to avert a hidden trap: the severe obturator nerve re-flex.
    Int Braz J Urol. 2021;47:594-595.
    PubMed    


  176. KHAN MT, Yang L, More E, Irlam-Jones JJ, et al
    Developing Tumor Radiosensitivity Signatures Using LncRNAs.
    Radiat Res. 2021;195:324-333.
    PubMed    
    Abstract available

  177. BRADBURY ML, Mullin CM, Gillian SD, Weisse C, et al
    Clinical outcomes of dogs with transitional cell carcinoma receiving medical therapy, with and without partial cystectomy.
    Can Vet J. 2021;62:133-140.
    PubMed    
    Abstract available

  178. ATLI SEKEROGLU Z, Sekeroglu V, Kontas Yedier S, Ilkun E, et al
    Increased DNA strand breaks and neoplastic transformation in human bladder cells treated with pioglitazone.
    Environ Mol Mutagen. 2021;62:143-154.
    PubMed    
    Abstract available

  179. HUANG S, Chen H, Li T, Pu X, et al
    Comparison of survival in elderly patients treated with uretero-cutaneostomy or ileal conduit after radical cystectomy.
    BMC Geriatr. 2021;21:49.
    PubMed    
    Abstract available

  180. GRANT EJ, Yamamura M, Brenner AV, Preston DL, et al
    Radiation Risks for the Incidence of Kidney, Bladder and Other Urinary Tract Cancers: 1958-2009.
    Radiat Res. 2021;195:140-148.
    PubMed    
    Abstract available

  181. DJORDJEVIC D, Vukovic M
    Functional results of hautmann neobladder with chimney modification and wallace ureteroileal anastomosis: initial experience with 22 patients.
    Int Braz J Urol. 2021;47:426-435.
    PubMed    
    Abstract available

  182. JOHNSON SM, Khararjian A, Legesse TB, Khani F, et al
    Nested Variant of Urothelial Carcinoma Is a Luminal Bladder Tumor With Distinct Coexpression of the Basal Marker Cytokeratin 5/6.
    Am J Clin Pathol. 2021;155:588-596.
    PubMed    
    Abstract available

  183. DOS REIS RB, Muglia VF, Rodrigues AA Junior, Viani G, et al
    Editorial Comment: Endoclips as novel fiducial markers in trimodality bladder preserving therapy of muscle-invasive bladder carcinoma: feasibility and patient out-comes.
    Int Braz J Urol. 2021;47:100-102.
    PubMed    


  184. CHEN S, Zhang N, Wang T, Zhang E, et al
    Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.
    Front Immunol. 2020;11:1900.
    PubMed    
    Abstract available

  185. JIANG Y, Wang Y, Li C, Zou Z, et al
    Development of an Immune-Related Risk Signature in Patients with Bladder Urothelial Carcinoma.
    Biomed Res Int. 2020;2020:5848493.
    PubMed    
    Abstract available

  186. LUO Q, Zhang X
    Construction of Protein-related Risk Score Model in Bladder Urothelial Carcinoma.
    Biomed Res Int. 2020;2020:7147824.
    PubMed    
    Abstract available

  187. STROCK V, Holmang S
    Is bladder tumour fulguration under local anaesthesia more painful than cystoscopy only?
    Scand J Urol. 2020;54:277-280.
    PubMed    
    Abstract available

  188. TAKAMA H, Shibata T, Ando Y, Yanagishita T, et al
    Pembrolizumab-induced psoriasis vulgaris successfully treated with apremilast.
    Eur J Dermatol. 2020;30:188-190.
    PubMed    


  189. TAN WS, Wang Y, Trinh QD, Preston MA, et al
    Delayed blood transfusion is associated with mortality following radical cystectomy.
    Scand J Urol. 2020;54:290-296.
    PubMed    
    Abstract available

  190. DEUKER M, Franziska Stolzenbach L, Rosiello G, Luzzago S, et al
    Radical cystectomy improves survival in patients with stage T1 squamous cell carcinoma and neuroendocrine carcinoma of the urinary bladder.
    Eur J Surg Oncol. 2021;47:463-469.
    PubMed    
    Abstract available

  191. JIN YY, Tong SQ, Tong M
    Erdafitinib exerts the anticancer effect on urothelial carcinoma via induction of authophagy.
    Pharmazie. 2020;75:195-197.
    PubMed    
    Abstract available

  192. SHAHBAZ M, Ammar A, Wang Y, Farhaj Z, et al
    Endoclips as novel fiducial markers in trimodality bladder-preserving therapy of muscle-invasive bladder carcinoma: feasibility and patient outcomes.
    Int Braz J Urol. 2021;47:93-99.
    PubMed    
    Abstract available

  193. WU WR, Lin JT, Pan CT, Chan TC, et al
    Amplification-driven BCL6-suppressed cytostasis is mediated by transrepression of FOXO3 and post-translational modifications of FOXO3 in urinary bladder urothelial carcinoma.
    Theranostics. 2020;10:707-724.
    PubMed    
    Abstract available

  194. LIN C, Yuan H, Wang W, Zhu Z, et al
    Importance of PNO1 for growth and survival of urinary bladder carcinoma: Role in core-regulatory circuitry.
    J Cell Mol Med. 2020;24:1504-1515.
    PubMed    
    Abstract available

  195. COWAN B, Klein E, Jansz K, Westenfelder K, et al
    Longitudinal Follow-up and Performance Validation of a mRNA-based Urine Test (Xpert(R) Bladder Cancer Monitor) for surveillance in Non-Muscle Invasive Bladder Cancer Patients.
    BJU Int. 2021 Apr 1. doi: 10.1111/bju.15418.
    PubMed    
    Abstract available

  196. STROTHER MC, Kutikov A, Epstein M, Bochner E, et al
    Safety of Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer and Malignant Ureteral Obstruction.
    BJU Int. 2021 Mar 29. doi: 10.1111/bju.15410.
    PubMed    
    Abstract available

  197. KHAN MT, Irlam-Jones JJ, Pereira RR, Lane B, et al
    A miRNA signature predicts benefit from addition of hypoxia-modifying therapy to radiation treatment in invasive bladder cancer.
    Br J Cancer. 2021 Apr 12. pii: 10.1038/s41416-021-01326.
    PubMed    
    Abstract available

  198. PINAR U, Pradere B, Roupret M
    Artificial intelligence in bladder cancer prognosis: a pathway for personalized medicine.
    Curr Opin Urol. 2021 Apr 20. pii: 00042307-900000000-98882.
    PubMed    
    Abstract available

  199. NECCHI A, de Jong JJ, Raggi D, Briganti A, et al
    Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab.
    Eur Urol. 2021 Mar 27. pii: S0302-2838(21)00212.
    PubMed    
    Abstract available

  200. DURDIN T, Goh A, Pietzak E
    Can an Imaging-guided Pathway Replace the Current Paradigm for Muscle-invasive Bladder Cancer?
    Eur Urol. 2021 Apr 8. pii: S0302-2838(21)00224.
    PubMed    


  201. ROUMIGUIE M, Contreras-Sanz A, Black PC
    Re: Ming Yuen Teo, Jose Mauricio Mota, Karissa A. Whiting, et al. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.
    Eur Urol. 2021 Apr 7. pii: S0302-2838(21)00234.
    PubMed    


  202. TEOH JY
    Editorial Comment to Use of surgical checklist during transurethral resection increases detrusor muscle collection rate and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer.
    Int J Urol. 2021 Mar 28. doi: 10.1111/iju.14563.
    PubMed    


  203. HATANO K, Nonomura N
    Editorial Comment from Dr Hatano and Dr Nonomura to Temporal trends in the incidence of distant-stage bladder cancer among young individuals.
    Int J Urol. 2021 Mar 28. doi: 10.1111/iju.14559.
    PubMed    


  204. SETOGUCHI K, Saito K
    Editorial Comment from Dr Setoguchi and Dr Saito to Laparoscopic versus open radical cystectomy in 607 patients with bladder cancer: Comparative survival analysis.
    Int J Urol. 2021 Mar 27. doi: 10.1111/iju.14561.
    PubMed    


  205. YAMASHITA S, Iguchi T, Koike H, Wakamiya T, et al
    Impact of preoperative sarcopenia and myosteatosis on prognosis after radical cystectomy in patients with bladder cancer.
    Int J Urol. 2021 Apr 5. doi: 10.1111/iju.14569.
    PubMed    
    Abstract available

  206. HAYASHI Y, Fujita K, Banno E, Eich ML, et al
    Telomerase reverse transcriptase promoter mutation in tumorigenesis of bladder cancer: Evolutionary trajectory by algorithmic inference from cross-sectional data.
    Int J Urol. 2021 Apr 15. doi: 10.1111/iju.14574.
    PubMed    


  207. LONATI C, Moschini M
    Editorial Comment from Dr Lonati and Dr Moschini to Impact of preoperative sarcopenia and myosteatosis on prognosis after radical cystectomy in patients with bladder cancer.
    Int J Urol. 2021 Apr 22. doi: 10.1111/iju.14577.
    PubMed    


  208. URABE F
    Editorial Comment from Dr Urabe to Telomerase reverse transcriptase promoter mutation in tumorigenesis of bladder cancer: Evolutionary trajectory by algorithmic inference from cross-sectional data.
    Int J Urol. 2021 Apr 21. doi: 10.1111/iju.14580.
    PubMed    


  209. SAITO R
    Editorial Comment from Dr Saito to Use of surgical checklist during transurethral resection increases detrusor muscle collection rate and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer.
    Int J Urol. 2021 Apr 21. doi: 10.1111/iju.14588.
    PubMed    


  210. KIJIMA T
    Editorial Comment from Dr Kijima to Impact of preoperative sarcopenia and myosteatosis on prognosis after radical cystectomy in patients with bladder cancer.
    Int J Urol. 2021 Apr 21. doi: 10.1111/iju.14581.
    PubMed    


  211. LUSTY A, Doiron RC, Booth CM, Whitehead M, et al
    No Outcome Differences after Cystectomy Between Patients with de Novo Muscle-Invasive Bladder Cancer Compared to Progressors: A Retrospective Population-Based Study.
    J Urol. 2021 Mar 30:101097JU0000000000001715. doi: 10.1097/JU.0000000000001715.
    PubMed    
    Abstract available

  212. YANAGISAWA T, Miki J, Sakanaka K, Fukuokaya W, et al
    Clinical Significance of Horizontal and Vertical Margin of En Bloc Resection for Non-Muscle Invasive Bladder Cancer.
    J Urol. 2021 Mar 29:101097JU0000000000001735. doi: 10.1097/JU.0000000000001735.
    PubMed    
    Abstract available

  213. SOUNTOULIDES P, Pyrgidis N, Brookman-May S, Mykoniatis I, et al
    Does Ureteral Stenting Increase the Risk of Metachronous Upper Tract Urothelial Carcinoma in Patients with Bladder Tumors? A Systematic Review and Meta-analysis.
    J Urol. 2021;205:956-966.
    PubMed    
    Abstract available

  214. BAUSCH K, Halbeisen FS, Aghlmandi S, Sutter SU, et al
    Antimicrobial Prophylaxis for Postoperative Urinary Tract Infections in Transurethral Resection of Bladder Tumors: A Systematic Review and Meta-analysis.
    J Urol. 2020 Dec 7:101097JU0000000000001513. doi: 10.1097/JU.0000000000001513.
    PubMed    
    Abstract available

  215. SHVERO A, Abu-Ghanem Y, Laufer M, Dotan ZA, et al
    Endoscopic Treatment for Large Multifocal Upper Tract Urothelial Carcinoma.
    J Urol. 2021;205:1039-1046.
    PubMed    
    Abstract available

  216. DAS A, Cohen JE, Ko OS, Jordan BJ, et al
    Surgeon Scorecards Improve Muscle Sampling on Transurethral Resection of Bladder Tumor and Recurrence Outcomes in Patients with Nonmuscle Invasive Bladder Cancer.
    J Urol. 2021;205:693-700.
    PubMed    
    Abstract available

  217. TAGUCHI S, Tambo M, Watanabe M, Machida H, et al
    Prospective Validation of Vesical Imaging-Reporting and Data System Using a Next-Generation Magnetic Resonance Imaging Scanner-Is Denoising Deep Learning Reconstruction Useful?
    J Urol. 2021;205:686-692.
    PubMed    
    Abstract available

  218. SWAMI U, Haaland B, Kessel A, Nussenzveig R, et al
    Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial Carcinoma.
    J Urol. 2021;205:709-717.
    PubMed    
    Abstract available

  219. BREE KK, Hensley PJ, Westerman MB, Kokorovic A, et al
    Contemporary Rates of Gynecologic Organ Involvement in Females With Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy Following Neoadjuvant Chemotherapy.
    J Urol. 2021 Apr 19:101097JU0000000000001784. doi: 10.1097/JU.0000000000001784.
    PubMed    
    Abstract available

  220. CHEN P, Chen J, He L, Du C, et al
    Identification of circRNA-miRNA-mRNA Regulatory Network in Bladder Cancer by Integrated Analysis.
    Urol Int. 2021 Mar 31:1-11. doi: 10.1159/000512066.
    PubMed    
    Abstract available

  221. LIU Y, Huang X, Guo L, Luo N, et al
    LINC00649 Facilitates the Cellular Process of Bladder Cancer Cells via Signaling Axis miR-16-5p/JARID2.
    Urol Int. 2021 Mar 31:1-9. doi: 10.1159/000506239.
    PubMed    
    Abstract available

  222. LIU Z, Zhang Y, Sun G, Ouyang W, et al
    Comparison of Thulium Laser Resection of Bladder Tumors and Conventional Transurethral Resection of Bladder Tumors for Non-Muscle-Invasive Bladder Cancer.
    Urol Int. 2021 Mar 30:1-6. doi: 10.1159/000514042.
    PubMed    
    Abstract available

  223. FROEHNER M, Koch R, Heberling U, Borkowetz A, et al
    Validation of a Questionnaire-Suitable Comorbidity Index in Patients Undergoing Radical Cystectomy.
    Urol Int. 2020;104.
    PubMed    
    Abstract available

  224. FEDELI U, De Paoli A, Corti MC, Cacciamani GE, et al
    Perioperative Mortality and Long-Term Survival after Radical Cystectomy: A Population-Based Study in a Southern European Country on 4,389 Patients.
    Urol Int. 2020;104.
    PubMed    
    Abstract available

  225. TAMALUNAS A, Buchner A, Kretschmer A, Jokisch F, et al
    Impact of Routine Laboratory Parameters in Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: A Long-Term Follow-Up.
    Urol Int. 2020;104.
    PubMed    
    Abstract available

  226. NARAIN TA, Tosh JM, Gautam G, Talwar HS, et al
    Neoadjuvant therapy for cisplatin ineligible muscle invasive bladder cancer patients: A review of available evidence.
    Urology. 2021 Mar 24. pii: S0090-4295(21)00267.
    PubMed    
    Abstract available

  227. SHA ST, Dee EC, Mossanen M, Mahal BA, et al
    Clinical characterization of radiation-associated muscle-invasive bladder cancer.
    Urology. 2021 Apr 12. pii: S0090-4295(21)00318.
    PubMed    
    Abstract available

  228. MANZANO RG, Catalan-Latorre A, Brugarolas A
    RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    BMC Cancer. 2021;21:432.
    PubMed    
    Abstract available

  229. TIAN Z, Meng L, Wang X, Diao T, et al
    Young age increases the risk of lymph-node metastasis in patients with muscle-invasive bladder urothelial carcinoma.
    BMC Cancer. 2020;20:851.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;